Cellebrite DI (CLBT) has released an update.
Cellebrite DI reports a robust start to 2024 with a 27% year-over-year increase in Annual Recurring Revenue (ARR) hitting $331.8 million, and a 26% surge in Q1 revenue amounting to $89.6 million, primarily driven by a significant 29% growth in subscription revenue. The company also notes a solid adjusted EBITDA of $17.6 million, attributing its strong performance to global business expansion and the successful market adoption of its new Inseyets digital forensics software.
For further insights into CLBT stock, check out TipRanks’ Stock Analysis page.
